At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 57 enrolled
Drug / intervention
RC48-ADCdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Tolerance, Safety and Pharmacokinetic Ascending Dose Phase I Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive Malignant in Advanced Malignant Solid Tumors
In Brief
A Phase 1 clinical trial evaluating RC48-ADC for Solid Tumors. Completed, enrolled 57 participants across 1 site.
Detailed Summary
A tolerance, safety and pharmacokinetic ascending dose phase I Study of RC48-ADC administered intravenously to subjects with HER2-positive malignant in advanced malignant solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartDec 2015
First PostedAug 2016
Primary CompletionJun 2019
Study CompletionNov 2019
TodayJul 2026
First PostedAug 26, 2016
Enrollment StartDec 14, 2015
Primary CompletionJun 27, 2019
Study CompletionNov 8, 2019
TodayJul 1, 2026
Enrollment to primary: 3.5 yearsPosted 9.8 years ago
Interventions
RC48-ADCdrug